Predictive biomarkers of overall survival in patients with renal cell carcinoma treated with interferon alpha +/- bevacizumab: Results from CALGB 90206 (Alliance).

CALGB 90206 was a phase III trial of 732 mRCC patients comparing bevacizumab plus interferon alpha (BEV+IFN) versus interferon alpha alone (IFN). No difference in overall survival (OS) was observed.